Home

The Korea Herald

Latest news

Most Popular

  1. 1

    Contentious grain bill put directly to plenary meeting for vote

    Contentious grain bill put directly to plenary meeting for vote
  2. 2

    Yoon's approval rating plunges to all-time low

    Yoon's approval rating plunges to all-time low
  3. 3

    Will tug-of-war between doctors, government end soon?

    Will tug-of-war between doctors, government end soon?
  4. 4

    Climate impacts set to cut 2050 global GDP by nearly a fifth

    Climate impacts set to cut 2050 global GDP by nearly a fifth
  5. 5

    Trilateral talks acknowledge ‘serious’ slumps of won, yen

    Trilateral talks acknowledge ‘serious’ slumps of won, yen
  1. 6

    [Graphic News] More Koreans say they plan long-distance trips this year

    [Graphic News] More Koreans say they plan long-distance trips this year
  2. 7

    [KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs

    [KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs
  3. 8

    North Korea removes streetlights along cross-border roads with South

    North Korea removes streetlights along cross-border roads with South
  4. 9

    Russia's denial of entry of S. Korean national unrelated to bilateral ties: Seoul official

    Russia's denial of entry of S. Korean national unrelated to bilateral ties: Seoul official
  5. 10

    Farming households dip below 1m for first time in 2023

    Farming households dip below 1m for first time in 2023
피터빈트

Samsung Bioepis' Humira biosimilar gains ground in Europe

By Yonhap

Published : Dec. 10, 2018 - 10:42

    • Link copied

Samsung Bioepis' Imraldi, a biosimilar for Humira, has earned more than 60 percent of the market in Germany, solidifying its landing in the European market, industry data indicated Monday.

The tally, as of Nov. 13 by market researcher IQVIA, showed Imraldi accounted for 62 percent of the biosimilar market for Humira in Germany. The figure was reached less than a month after the South Korean drug company launched Imraldi in Europe on Oct. 17.


(Yonhap) (Yonhap)

The Samsung affiliate had competed with Sandoz and Amgen, who released their own Humira biosimilars in Europe in mid-October.

While the early mover usually commands advantage, the market reaction is uncertain when competing products are launched simultaneously.

Germany has the biggest market in Europe for Humira, about 28 percent of the continent, worth 1.3 trillion won ($1.15 billion) last year.

The biosimilars, however, lag far behind the original Humira in market size, data showed. In case of Imraldi, it accounts for 6.8 percent of the total market for Humira and its biosimilars. (Yonhap)

More from Headlines